- Home
- GRX vs PBYI Comparison
GRX vs PBYI Comparison
Compare GRX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- PBYI
- Stock Information
- Founded
- GRX 2007
- PBYI 2010
- Country
- GRX United States
- PBYI United States
- Employees
- GRX N/A
- PBYI N/A
- Industry
- GRX Finance/Investors Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- PBYI Health Care
- Exchange
- GRX Nasdaq
- PBYI Nasdaq
- Market Cap
- GRX 145.5M
- PBYI 171.7M
- IPO Year
- GRX N/A
- PBYI N/A
- Fundamental
- Price
- GRX $9.34
- PBYI $5.73
- Analyst Decision
- GRX
- PBYI Strong Buy
- Analyst Count
- GRX 0
- PBYI 1
- Target Price
- GRX N/A
- PBYI $7.00
- AVG Volume (30 Days)
- GRX 39.7K
- PBYI 736.1K
- Earning Date
- GRX 01-01-0001
- PBYI 08-07-2025
- Dividend Yield
- GRX 5.98%
- PBYI N/A
- EPS Growth
- GRX N/A
- PBYI 434.29
- EPS
- GRX 0.26
- PBYI 0.97
- Revenue
- GRX N/A
- PBYI $238,062,000.00
- Revenue This Year
- GRX N/A
- PBYI N/A
- Revenue Next Year
- GRX N/A
- PBYI N/A
- P/E Ratio
- GRX $38.50
- PBYI $5.89
- Revenue Growth
- GRX N/A
- PBYI 8.63
- 52 Week Low
- GRX $7.73
- PBYI $2.23
- 52 Week High
- GRX $10.40
- PBYI $5.81
- Technical
- Relative Strength Index (RSI)
- GRX 54.66
- PBYI 88.88
- Support Level
- GRX $8.93
- PBYI $3.05
- Resistance Level
- GRX $9.30
- PBYI $5.06
- Average True Range (ATR)
- GRX 0.11
- PBYI 0.35
- MACD
- GRX 0.02
- PBYI 0.27
- Stochastic Oscillator
- GRX 89.13
- PBYI 97.16
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.